Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 31, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Maintained (VERA) at Buy with Increased Target to $65 on, May 31st, 2024
Anupam Rama of JP Morgan, Maintained "Vera Therapeutics, Inc." (VERA) at Buy with Increased Target from $60 to $65 on, May 31st, 2024.
Anupam has made no other calls on VERA in the last 4 months.
There are 3 other peers that have a rating on VERA. Out of the 3 peers that are also analyzing VERA, 1 agrees with Anupam's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $34 on, Thursday, March 21st, 2024
These are the ratings of the 2 analyists that currently disagree with Anupam
- Steven Seedhouse of "Raymond James" Maintained at Strong Buy with Increased Target to $68 on, Friday, May 10th, 2024
- Vamil Divan of "Guggenheim" Reiterated at Strong Buy and Held Target at $56 on, Friday, April 5th, 2024
